AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
September 12 2022 - 7:30AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced that the company has sold its royalty interest on
future global net sales of Zejula to a wholly-owned subsidiary of
DRI Healthcare Trust for up to $45 million.
AnaptysBio has received a $35 million upfront payment for the
sale of its 1% royalty on global net sales of Zejula which, due to
reductions relating to third party royalties, is paid at an
effective rate of 0.5%. The company is also eligible to receive a
further $10 million from DRI upon FDA approval of Zejula for the
treatment of endometrial cancer, for which the drug is currently in
a fully-enrolled ongoing Phase 3 study, to the extent that such
approval occurs on or before December 31, 2025.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company focused on delivering innovative immunology
therapeutics. We are developing immune cell modulators, including
two checkpoint agonists in clinical-stage development, for
autoimmune and inflammatory disease: rosnilimab, our anti-PD-1
agonist program in Phase 2 for the treatment of moderate-to-severe
alopecia areata; and ANB032, our anti-BTLA agonist program, which
is broadly applicable to human inflammatory diseases associated
with lymphoid and myeloid immune cell dysregulation. AnaptysBio is
also developing imsidolimab, our anti-IL-36R antibody in Phase 3
for the treatment of generalized pustular psoriasis, or GPP.
AnaptysBio’s antibody pipeline has been developed using our
proprietary somatic hypermutation, or SHM platform, which uses in
vitro SHM for antibody discovery and is designed to replicate key
features of the human immune system to overcome the limitations of
competing antibody discovery technologies. AnaptysBio has also
developed multiple therapeutic antibodies in an immuno-oncology
collaboration with GSK, including an anti-PD-1 antagonist antibody
(JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist
antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist
antibody (GSK4074386).
About DRI Healthcare TrustDRI Healthcare Trust
is managed by DRI Capital Inc. (“DRI”), the pioneer in global
pharmaceutical royalty monetization with a more than 30-year
history of accelerating innovation by providing capital to
inventors, academic institutions and biopharma companies. Since our
founding in 1989, DRI has deployed more than $2 billion, acquiring
more than 60 royalties on 40-plus drugs, including Eylea, Spinraza,
Zytiga, Remicade, Keytruda and Stelara. DRI Healthcare Trust’s
units are listed and trade on the Toronto Stock Exchange in
Canadian dollars under the symbol “DHT.UN” and in U.S. dollars
under the symbol “DHT.U”. To learn more, visit
drihealthcaretrust.com or follow us on LinkedIn.
Contacts:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024